Oncolytics Biotech Inc. has made a significant announcement regarding its REO 033 trial, which will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. This trial-in-progress abstract aims to showcase the potential of pelareorep in treating colorectal cancer, a critical area in the pharmaceutical preparations sector.
Oncolytics Biotech Inc. is a clinical-stage immunotherapy company based in San Diego, California, focused on developing innovative treatments for cancer. The company operates under the ticker symbol ONCY on the Nasdaq exchange and is categorized under the SIC code 2834, which pertains to pharmaceutical preparations. Recent filings indicate that Oncolytics is actively engaged in advancing its clinical trials and research efforts.
The filing notes that on October 20, 2026, Oncolytics Biotech issued a press release detailing the REO 033 trial-in-progress abstract. This study evaluates pelareorep in combination with standard treatments for patients with RAS-mutant, microsatellite-stable metastatic colorectal cancer. The company aims to validate encouraging efficacy signals observed in previous trials.
Highlights from the REO 033 trial include a randomized, controlled study involving patients who have previously undergone oxaliplatin-based therapy. The study will compare the effectiveness of pelareorep combined with FOLFIRI and bevacizumab against the standard treatment of FOLFIRI and bevacizumab. The primary endpoint of the trial is the objective response rate, with secondary endpoints focusing on overall survival and progression-free survival.
This development is crucial for various stakeholders, including patients, healthcare providers, and investors in the pharmaceutical industry. The trial's outcomes could influence treatment protocols and regulatory decisions, potentially leading to new standards of care in oncology.
The filing does not specify what happens next, but the ongoing research and presentation at ESMO 2026 indicate that Oncolytics Biotech is committed to advancing its clinical programs and engaging with the medical community.